Sunday 18 October 2026
Export RNA’s income statement to Excel — free account
Atrium Therapeutics, Inc.
RNA
Atrium Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $18.8 million, up 72.1% from fiscal 2024. Revenue growth for three consecutive years.
7.67
0.15
−1.92%
Follow RNA
| Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 7.49 | 17.06 | 12.86 | 13.73 | 6.22 | 14.64 | 8.68 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
(21.19) | (21.19) | (21.19) | (21.19) | (21.19) | (21.19) | (21.19) | (21.19) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
— | 9.24 | 22.50 | 13.67 | 11.77 | 7.38 | 15.32 | 8.68 |
Current Ratio |
— | 9.35 | 22.74 | 13.86 | 12.00 | 7.58 | 15.73 | 9.20 |
Net Debt/EBITDA |
0.00 | 33.23 | 49.16 | 24.04 | 21.42 | 13.34 | 19.93 | 9.08 |
Debt/Assets |
0.00% | 1.83% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.05 | 0.03 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Coverage |
(2.87) | (0.38) | (31.94) | — | — | — | — | — |
| 0.00% | 0.00% | 99.98% | 94.00% | 64.08% | 45.67% | 44.04% | 55.42% | |
| 0.00% | (51.05%) | (20.59%) | (30.99%) | (32.63%) | (33.49%) | (29.40%) | (38.88%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
0.00% | (28.74%) | (13.92%) | (30.55%) | (30.14%) | (39.37%) | (22.12%) | (42.10%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
644.06% | 220.44% | 198.35% | 280.88% | 409.07% | 566.84% | 791.41% | 1,095.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.27) | (0.27) | (0.27) | (0.27) | (0.27) | (0.27) | (0.27) | (0.27) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(24.82%) | (24.82%) | (24.82%) | (24.82%) | (24.82%) | (24.82%) | (24.82%) | (24.82%) |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Shareholders Equity per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Debt per Share |
— | 0.00 | — | — | — | — | — | — |
Working Capital |
— | 85.44 | 317.09 | 381.48 | 571.03 | 530.63 | 1,444.27 | 1,603.02 |
Net Current Asset Value |
— | 68.13 | 304.00 | 364.99 | 562.22 | 483.52 | 1,403.35 | 1,529.02 |
Average Assets |
— | 48.45 | 215.40 | 380.74 | 533.19 | 633.68 | 1,096.23 | 1,760.97 |
Average Common Equity |
— | — | (44.36) | (125.54) | (271.55) | (464.65) | (731.91) | (1,235.38) |
Columns are period end dates